Weekly news

Tooth-regeneration drug set for first trials in target patients

Scientists have begun the first human trials of a drug that could help people regrow missing teeth by blocking a protein called USAG-1.

Scientists have begun the first human trials of a drug that could help people regrow missing teeth! The treatment works by blocking a protein called USAG-1, allowing the body to naturally grow new teeth.

It is currently being tested on patients born with missing permanent teeth. If successful, this breakthrough could change the future of dentistry by helping people regrow their own natural teeth instead of relying on implants or dentures.

Although the drug is still being tested, it offers hope for a more permanent and natural solution to tooth loss.

• ✅A new drug blocks the USAG-1 protein to help the body naturally regrow teeth.
• ✅First human trials are underway in patients born with missing permanent teeth.
• ✅If successful, it could replace implants and dentures with real, regrown teeth.

FDA approves first at-home starting dose for Alzheimer's disease treatment

Check out this article published under the FDA. Patients in the early stages of Alzheimer's can now start Leqembi with an injection at home instead of a clinic IV.

The FDA has approved the first at-home starting dose of Leqembi, a treatment for people in the early stages of Alzheimer’s disease. Instead of traveling to a clinic for IV infusions, patients or their caregivers can now start treatment with an injection at home.

Leqembi works by reducing harmful protein plaques in the brain, which can help slow memory and thinking decline. While the treatment still has some risks and requires medical monitoring, this approval makes Alzheimer’s care more convenient and accessible for many families.

Stay tuned for our next weekly publish!

• ✅First at-home starting dose of Leqembi approved for early-stage Alzheimer’s.
• ✅Leqembi reduces harmful brain plaques to help slow memory and thinking decline.
• ✅Still requires medical monitoring, but makes care far more accessible.

5 notable approvals in therapies regarding obesity, AML, kidney disease, hearing loss, and bladder cancer

Check out this article written by Ella Hohmann, fact checked by Pearl Steinzor. The first half of 2026 was a major milestone for medicine.

The first half of 2026 was a major milestone for medicine, with the FDA approving several innovative treatments that could improve or even transform the lives of many patients. These new therapies focus on making treatment more effective, more convenient, and, in some cases, targeting diseases at their source.

Some of the biggest approvals included the first daily GLP-1 weight-loss pill, the first fully oral treatment for acute myeloid leukemia (AML), the first FDA-approved drug for a rare kidney disease called FSGS, the first gene therapy for inherited hearing loss, and a new immunotherapy for high-risk bladder cancer that reduces the risk of the disease returning.

Together, these breakthroughs show how quickly medicine is advancing. From gene therapy to easier-to-take medications, these approvals offer new hope and better treatment options for people living with serious illnesses.

• ✅First daily GLP-1 weight-loss pill and first fully oral AML treatment approved.
• ✅First-ever approved drug for the rare kidney disease FSGS, plus a gene therapy for inherited hearing loss.
• ✅New immunotherapy lowers the risk of high-risk bladder cancer returning.

A new drug is changing survival rates for one of the deadliest cancers

Check out this article written by Todd Neff. Pancreatic cancer is one of the most difficult cancers to treat — but an experimental drug called daraxonrasib is showing real promise.

Pancreatic cancer is one of the most difficult cancers to treat; however, an experimental drug is showing potential results. Researchers are using the new drug called daraxonrasib, and it has had outstanding results. In the most recent trial, patients who received the drug lived for much longer periods of time compared to those who had conventional treatment. The drug targets a unique gene that most pancreatic cancers have, which scientists have found difficult to attack in the past.

Although this drug isn’t a cure, it is one of the biggest advances for pancreatic cancer yet. The effects the patients suffered were manageable, and the research done in its trial was powerful enough for the rest of the medical world to be aware. Paired with cancer vaccines, the results of the drug could make the lives of pancreatic patients more manageable than before. The progress also helps in the advance of cancer vaccines and AI detecting cancer early.

• ✅Daraxonrasib targets a gene mutation found in most pancreatic cancers.
• ✅Trial patients lived noticeably longer than those on conventional treatment.
• ✅Side effects were manageable — promising, but not a cure yet.